First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Recruiting

Phase 1

Phase 2

CRB-601-01First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Sponsor:

Corbus Pharmaceuticals Inc.

Code:

NCT06603844

Conditions

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CRB-601 monoclonal antibody

Anti-PD-1 monoclonal antibody

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Corbus Pharmaceuticals Inc. on 2025-06-03.